ArticleBMC oral health2026
Regulatory effects of transcription factor PAX3 on human dental pulp stem cells.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundDental pulp stem cells (DPSCs) are promising for regenerative dentistry but undergo replicative senescence during in vitro expansion, leading to diminished proliferative capacity and osteogenic potential. This study aimed to investigate the role of the transcription factor PAX3 in regulating the senescence process of human DPSCs (hDPSCs).
methodsA replicative senescence model of hDPSCs was established through serial passaging (P3 as young cells vs. P11 as senescent cells). The expression of PAX3 and senescence markers (p53, p21) was assessed. The functional role of PAX3 was investigated by knocking it down (si-PAX3) or overexpressing it (OE-PAX3) in hDPSCs, followed by evaluations of senescence-associated β-galactosidase (SA-β-gal) activity, cell proliferation, and osteogenic differentiation.
resultsPAX3 expression was significantly downregulated in senescent P11 hDPSCs compared to young P3 cells. Functionally, PAX3 knockdown was associated with accelerated cellular senescence, as evidenced by increased SA-β-gal activity, upregulation of p53 and p21 mRNA levels, impaired cell proliferation, and reduced osteogenic differentiation. Conversely, PAX3 overexpression was associated with an attenuated senescent phenotype, resulting in decreased SA-β-gal activity and expression of p53/p21, enhanced proliferation, and improved osteogenic capacity.
conclusionThe transcription factor PAX3 may play a critical regulatory role in mitigating hDPSCs senescence, as downregulation of PAX3 was associated with increased senescence markers and its overexpression with reduced senescence markers. The observed correlation with p53/p21 mRNA levels suggests that this pathway may be involved, but mechanistic validation at the protein level is still required. These findings indicate that PAX3 represents a candidate for further investigation as a potential target to delay senescence and maintain the functional properties of hDPSCs, warranting further investigation for its potential utility in tissue engineering and clinical stem cell-based therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.